8-K: Passage Bio Announces Restructuring, Clinical Trial Updates, and Extended Cash Runway

Passage Bio is restructuring its operations, reducing its workforce by 55%, and transitioning to an outsourced analytical testing model, which extends its cash runway into the first quarter of 2027.

Summary

• Passage Bio announced a restructuring plan involving a 55% workforce reduction and the closure of its lab operations in New Jersey.
• The company expects to save $9.0 to $11.0 million annually from the restructuring, excluding $2.0 million in severance and exit costs.
• Impairment expenses for laboratory equipment are estimated to be between $1.0 and $3.0 million.
• The company's cash, cash equivalents, and marketable securities are approximately $76.8 million as of December 31, 2024.
• This cash position is expected to fund operations into the first quarter of 2027.
• Clinical trial data for PBFT02 shows a robust and durable increase in cerebrospinal fluid (CSF) progranulin (PGRN) expression in patients with frontotemporal dementia with GRN mutations (FTD-GRN).
• Plasma neurofilament light chain (NfL) levels were 13% lower than baseline on average at 12 months post-treatment, compared to an expected 29% increase per year in untreated patients.
• The company plans to evaluate a 50% lower dose of PBFT02 (Dose 2) in subsequent FTD-GRN and FTD-C9orf72 patients.
• Dosing of FTD-C9orf72 patients is expected to begin in the first half of 2025.
• The company has completed process development and scale-up of a high-productivity, suspension-based manufacturing process for PBFT02.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative news. The positive clinical trial data and extended cash runway are encouraging, but the restructuring and workforce reduction are concerning. Overall, the sentiment is cautiously optimistic.

Positives

• The company has extended its cash runway into the first quarter of 2027.
• Clinical trial data shows promising results for PBFT02, with increased CSF PGRN expression and reduced plasma NfL levels.
• The company has successfully developed a more efficient manufacturing process for PBFT02.
• The company is on track to initiate dosing of FTD-C9orf72 patients in the first half of 2025.
• The company is actively pursuing a regulatory pathway for PBFT02.

Negatives

• The company is undergoing a significant restructuring, including a 55% workforce reduction.
• The company is incurring $2.0 million in severance and exit costs.
• The company expects to recognize impairment expenses for laboratory equipment of $1.0 to $3.0 million.
• Two patients experienced serious adverse events (SAEs), including venous sinus thrombosis (VST) and hepatotoxicity in one patient, and VST in another, although both were resolved.

Risks

• The restructuring plan may not achieve the expected cost savings.
• The company may incur additional costs related to the restructuring.
• The clinical trial results are preliminary and may not be replicated in larger studies.
• The company may face challenges in obtaining regulatory approval for PBFT02.
• The company is dependent on third parties for manufacturing and analytical testing.
• The company is subject to risks associated with clinical trials, including unexpected concerns that may arise from additional data or analysis obtained during clinical trials.

Future Outlook

The company expects its current cash resources to fund operations into the first quarter of 2027. They plan to continue advancing the PBFT02 program, including evaluating a lower dose, initiating dosing in FTD-C9orf72 patients, and seeking regulatory feedback on the FTD-GRN registrational trial design.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that the clinical trial data shows that Dose 1 PBFT02 consistently increased CSF PGRN expression and that this elevation translated to early signals of improvement in a disease progression biomarker.
• Dr. Chou also mentioned that the company will transition to an outsourced analytical testing model and have restructured the organization and reduced operating expenses accordingly.
• Dr. Chou stated that the company is focused on advancing the upliFT-D study and bringing the therapy to the FTD patient community.

Industry Context

This announcement reflects a trend in the biotech industry where companies are focusing on cost-cutting measures and prioritizing key programs to extend their cash runway. The clinical trial data is significant in the context of the development of treatments for neurodegenerative diseases, where there is a high unmet need.

Comparison to Industry Standards

• The reported increase in CSF PGRN levels is a positive signal compared to the natural progression of FTD-GRN, where PGRN levels are typically low.
• The 13% reduction in plasma NfL levels at 12 months post-treatment is a notable improvement compared to the expected 29% annual increase in untreated patients, as reported in published natural history data.
• Other companies developing gene therapies for neurodegenerative diseases, such as uniQure and Sarepta Therapeutics, are also focused on demonstrating biomarker improvements and clinical efficacy in their trials.
• The move to an outsourced analytical testing model is a common strategy for biotech companies to reduce costs and focus on core competencies, similar to what other companies like Alnylam and BioMarin have done in the past.

Stakeholder Impact

• Shareholders may be concerned about the restructuring and workforce reduction, but encouraged by the extended cash runway and positive clinical trial data.
• Employees are significantly impacted by the 55% workforce reduction.
• Patients with FTD-GRN and FTD-C9orf72 may benefit from the continued development of PBFT02.
• Suppliers and vendors may be affected by the restructuring and changes in operations.

Next Steps

• Evaluate Dose 2 of PBFT02 in subsequent FTD-GRN and FTD-C9orf72 patients.
• Report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in the second half of 2025.
• Initiate dosing of FTD-C9orf72 patients in the first half of 2025.
• Seek regulatory feedback on FTD-GRN registrational trial design in the first half of 2026.

Key Dates

Keywords

PBFT02, Frontotemporal Dementia, FTD-GRN, FTD-C9orf72, Progranulin, PGRN, Neurofilament Light Chain, NfL, Gene Therapy, Clinical Trial, Restructuring, Cash Runway, Biomarkers, Manufacturing, Outsourcing